Remarkably, the administration of anti-PD-L1 significantly suppressed tumor progression (Fig. 6B–D), resulting in prolonged survival (Fig. 6E) and activated tumor immune response (Fig. 6H, I). The gene discussed is CD274; the disease is neoplasm.